Development of red blood cell autoantibodies following treatment with checkpoint inhibitors: a new class of anti-neoplastic, immunotherapeutic agents associated with immune dysregulation

1.Tarhini A. Immune-mediated adverse events associated with ipilimumab CTLA-4 blockade therapy: the underlying mechanisms and clinical management. Scientifica 2013: Article ID 857519. dx.doi.org/10.1155/2013/857519.10.1155/2013/857519382035524278787Search in Google Scholar

2.Hodi FS, O’Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010;363:711–23.10.1056/NEJMoa1003466354929720525992Search in Google Scholar

3.Gao J, He Q, Subudhi S, et al. Review of immune-related adverse events in prostate cancer patients treated with ipilimumab: MD Anderson experience. Oncogene 2015;34:5411–7.10.1038/onc.2015.5453009125659583Search in Google Scholar

4.Davids MS, Kim HT, Bachireddy P, et al. Ipilimumab for patients with relapse after allogeneic transplantation. N Engl J Med 2016;375:143–53.10.1056/NEJMoa1601202514945927410923Search in Google Scholar

5.Mahoney KM, Freeman GJ, McDermott DF. The next immune-checkpoint inhibitors: PD-1/PD-L1 blockade in melanoma. Clin Ther 2015;37:764–82.10.1016/j.clinthera.2015.02.018449795725823918Search in Google Scholar

6.Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366:2443–54.10.1056/NEJMoa1200690354453922658127Search in Google Scholar

7.Garon EB, Rizvi NA, Hui R, et al. Pembrolizumab for the treatment of non-small-cell lung cancer. N Engl J Med 2015;372:2018–20.10.1056/NEJMoa150182425891174Search in Google Scholar

8.Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus docetaxel in advanced squamous-cell non-small cell lung cancer. N Engl J Med 2015;373:123–35.10.1056/NEJMoa1504627468140026028407Search in Google Scholar

9.National Institutes of Health, Clinical Trials Web site. Available at https://ClinicalTrials.gov/. Last accessed 8/29/2016.Search in Google Scholar

10.Li S, Chen S, Yang L, Li Y. The role of PD-1 and PD-L1 in T-cell immune suppression in patients with hematological malignancies. J Hematol Oncol 2013;6:74.10.1186/1756-8722-6-74385197624283718Search in Google Scholar

11.Gibson R, Delaune J, Szady A, Markham M. Suspected autoimmune myocarditis and cardiac conduction abnormalities with nivolumab therapy for non-small cell lung cancer. BMJ Case Rep 2016. doi:10.1136/bcr-2016-216228.10.1136/bcr-2016-216228496414827440853Search in Google Scholar

12.Du Rusquec P, Saint-Jean M, Brocard A, et al. Ipilimumab-induced autoimmune pancytopenia in a case of metastatic melanoma. J Immunother 2014;37:348–50.10.1097/CJI.000000000000004124911795Search in Google Scholar

13.Gordon IO, Wade T, Chin K, Dickstein J, Gajewski TF. Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma. Cancer Immunol Immunother 2009;58:1351–3.10.1007/s00262-008-0627-x19052742Search in Google Scholar

14.Simeone E, Grimaldi AM, Esposito A, et al. Serious haematological toxicity during and after ipilimumab treatment: a case series. J Med Case Rep 2014;8:240.10.1186/1752-1947-8-240409065524986059Search in Google Scholar

15.Kong BY, Micklethwaite KP, Swaminathan S, Kefford RF, Carlino MS. Autoimmune hemolytic anemia induced by anti-PD-1 therapy in metastatic melanoma. Melanoma Res 2016;26:202–4.10.1097/CMR.000000000000023226795275Search in Google Scholar

16.Nair R, Gheith S, Nair SG. Immunotherapy-associated hemolytic anemia with pure red cell aplasia. N Engl J Med 2016;374:1096–7.10.1056/NEJMc150936226981948Search in Google Scholar

17.Judd WJ, Johnson ST, Storry JR. Judd’s methods in immunohematology. 3rd ed. Bethesda, MD: American Association of Blood Banks, 2008.Search in Google Scholar

18.Weldy L. Polyethylene glycol antiglobulin test (PEG-AGT). Immunohematology 2014:30:158–60.10.21307/immunohematology-2019-113Search in Google Scholar

19.Cappelli LC, Gutierrez AK, Baer AN, et al. Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab. Ann Rheum Dis 2017;76:43–50.10.1136/annrheumdis-2016-209595533399027307501Search in Google Scholar

20.Sun J, Schiffman J, Raghunath A, Ng Tang D, Chen H, Sharma P. Concurrent decrease in IL-10 with development of immune-related adverse events in a patient treated with anti-CTLA-4 therapy. Cancer Immun 2008;8:9.Search in Google Scholar

21.Von Euw E, Chodon T, Attar N, et al. CTLA4 blockade increases Th17 cells in patients with metastatic melanoma. J Transl Med 2009;7:35.10.1186/1479-5876-7-35269713719457253Search in Google Scholar

22.Ahmad E, Elgohary T, Ibrahim H. Naturally occurring regulatory T cells and interleukins 10 and 12 in the pathogenesis of idiopathic warm autoimmune hemolytic anemia. J Investig Allergol Clin Immunol 2011;21:297–304.Search in Google Scholar

23.Mqadmi A, Zheng X, Yazdanbakhsh K. CD4+CD25+ regulatory T cells control induction of autoimmune hemolytic anemia. Blood 2005;105:3746–8.10.1182/blood-2004-12-4692189501315637139Search in Google Scholar

24.Ward FJ, Hall AM, Cairns LS, et al. Clonal regulatory T cells specific for a red blood cell autoantigen in human autoimmune hemolytic anemia. Blood 2008;111:680–7.10.1182/blood-2007-07-101345257583817761830Search in Google Scholar